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Abstract
Background: Increasingly, researchers are recognizing that there are many situations where the
use of a cluster randomized trial may be more appropriate than an individually randomized trial.
Similarly, the need for appropriate standards of reporting of cluster trials is more widely
acknowledged.
Methods: In this paper, we describe the results of a survey to inform the appropriate reporting
of the intracluster correlation coefficient (ICC) – the statistical measure of the clustering effect
associated with a cluster randomized trial.
Results: We identified three dimensions that should be considered when reporting an ICC – a
description of the dataset (including characteristics of the outcome and the intervention),
information on how the ICC was calculated, and information on the precision of the ICC.
Conclusions: This paper demonstrates the development of a framework for the reporting of
ICCs. If adopted into routine practice, it has the potential to facilitate the interpretation of the
cluster trial being reported and should help the development of new trials in the area.
Background
In evaluative health care research, the randomized con-
trolled trial is generally considered the gold standard
design for assessing the relative effectiveness of alternative
interventions, as it ensures that selection bias and other
common sources of bias are minimized [1]. In most of
these trials, patients are allocated individually to the dif-
ferent treatments. It is being increasingly recognised, how-
ever, that there are many situations where randomizing by
groups of individuals may be more appropriate [2,3]. For
example, when assessing a dietary intervention, it is com-
mon to randomize families as an intact unit, to avoid the
possibility of different members of the same family being
assigned to different interventions. Trials that randomize
by groups are known as cluster randomized trials [3,4].
The adoption of a clustered design is not without cost,
however, as the design and conduct of these trials requires
special considerations. They are more complex to design,
they require more participants than an individually rand-
omized trial, and require more complex analysis. This
added complexity arises primarily because observations
on individuals within the same cluster may be correlated
– that is, the outcomes for individuals within clusters are
likely to be more similar than those across clusters. The
statistical measure of this 'clustering effect' is known as the
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intracluster correlation coefficient, or ICC [5]. The ICC for
a particular outcome can be described as the amount of
variation in the dataset that can be explained by the vari-
ation between clusters.
The need for clear reporting of randomized trials has been
widely recognised. This has been highlighted through the
publication of the CONSORT statement, which outlines
the common standards for the reporting of trials [6], and
through the revision to the statement published in 2001
[7]. The majority of the CONSORT work to date, however,
has been for individually randomized trials. Recent stud-
ies have, however, shown problems with the reporting of
cluster trials [8-10]. For example, ICCs were reported in
only 6/149 trials in the MacLennan study [8], in only 13/
152 trials in the Eldridge study [9] and in only 1/51 trials
in the Isaakidis study [10]. Two recent papers have there-
fore considered extensions to the CONSORT Statement
for the reporting of cluster trials [11,12].
To aid the interpretation of the results of cluster trials, it is
important that appropriate information is presented in
their reports. The ICC for each trial outcome is widely
acknowledged to be one of the primary factors which
helps researchers interpret the results of the trial. It also
helps researchers planning new trials in the area, as esti-
mates of ICCs are used to inform sample size calculations
– standard sample size calculations require to be inflated
by a factor:
1+(n-1)ρ
(where n is the average cluster size and ρ is the ICC for the
desired outcome) to accommodate for the lack of inde-
pendence in the data [3]. This factor is commonly called
the 'variance inflation factor' or the 'design effect' [3]. In
response to this, there have been calls to increase the
reporting of ICCs within the reports of cluster trials
[13,14]. Whilst the reporting of ICCs would appear to be
increasing (for example through several recent publica-
tions of collections of ICCs [14-16]), there is, however, lit-
tle consistency in the information presented to describe
the ICC.
The aim of this study, therefore, was to determine the
most appropriate descriptors for the reporting of an ICC,
by surveying researchers working in the field of cluster
trials.
Methods
Since 1998, at least three international workshops on
cluster randomized trials have been held in the UK, com-
prising researchers and statisticians involved in the design
and conduct of cluster trials. Across the three workshops,
119 researchers and statisticians with an interest in cluster
trials either attended, or expressed a wish to attend. These
individuals formed the primary population for the survey.
In addition, the UK Directory of Academic Statisticians
2001 [17] was searched for those expressing a special
interest in the field of cluster trials. This identified 11 stat-
isticians with an interest in the area. Ten of these were
already identified for inclusion in the survey; hence only
one additional statistician was identified through this
approach. This gave a final survey population of 120 indi-
viduals, representing researchers and statisticians from 11
countries (104 individuals from the UK; 3 from the Neth-
erlands; 2 each from Denmark, Finland and South Africa;
and 1 each from Norway, Switzerland, Spain, Canada,
USA, Australia and Thailand), which included known
leaders in the field.
A small focus group was held to develop the framing of a
questionnaire to identify descriptors of an ICC. This group
consisted of four statisticians and two triallists who were
experienced in the design and conduct of cluster trials. The
group felt that the inclusion of examples would facilitate
completion of the questionnaire, and generated a small
number of factors which might affect the interpretation of
the ICC. Examples included:
• the average cluster size (which is linked with the ICC in
generating sample size calculations);
• the number of clusters in the dataset;
• the setting (whether community or hospital);
• the country/countries involved in the trial;
• the disease or specialty grouping; and
• the type of outcome – whether process or outcome.
The survey population was then sent a postal question-
naire [see Additional File 1] and participants were encour-
aged to identify factors which they thought should be
used to describe an ICC. All questions in the question-
naire were of 'open' format (that is, allowing free-text
input) rather than tick-box format. Multiple suggestions
were permissible, and all free-text responses were subse-
quently coded by the same researcher (MKC). A reminder
questionnaire was sent out four weeks after dispatch, if no
response was obtained to the initial mailing.
Results
Of the 120 questionnaires dispatched, 78 were completed
(and a further questionnaire was returned as the named
individual was no longer at the listed address). This gave
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an adjusted response rate to the questionnaire of 66%
(78/119).
One hundred suggestions for appropriate descriptors of
an ICC were received (representing 34 separate compo-
nents). From these descriptors, it was possible a posteriori
to conceptualize the majority of these into three distinct
areas (Figure 1):
a) a description of the dataset and the outcome(s) (67
responses);
b) information on the method of calculation of the ICC
(18 responses); and
c) information on the precision of the ICC (12 responses).
Description of the dataset
Respondents identified three main elements that they
thought should be used to describe the dataset:
• the demographic distribution within and between clus-
ters (e.g. age, sex and ethnic distribution). It was thought
that different distributions across clusters could affect the
ICC.
• a description of the outcome – was it binary or continu-
ous, what was the underlying prevalence of the outcome
and was the outcome measured subjectively or objec-
tively? It was thought that outcomes that were measured
subjectively (eg physician assessment of well-being) were
likely to display greater clustering than those measured
objectively (eg laboratory-processed blood results).
• a description of the intervention. Individuals felt that
the interventions should be well described, in order to
identify whether specific components of an intervention
might be expected to have undue influence on the ICC.
For example, if health professional were the unit of allo-
cation and an intervention was designed to make health
professionals' practice more consistent, one might expect
Framework for describing ICCsigure 1
Framework for describing ICCs
Information on the 
precision of the ICC
Description of the 
dataset and the 
outcome(s)
Information on the 
calculation of ICC
• demographic 
distribution   of 
clusters
• description of 
outcome 
• prevalence of 
outcome
• description of 
intervention
ICC
• Method of calculation
• Software program used
• Adjusted (or not) for 
covariates
• Data used for calculation
• Confidence intervals
• Number of clusters
• Average cluster size
• Range (spread) of 
cluster sizes
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that an ICC based on data in the post-intervention phase
would be smaller than an ICC based on the pre-interven-
tion data (if the intervention was successful, it would
induce less variation between clusters, as health profes-
sionals would be more consistent after the intervention).
Calculation of the ICC
The second important dimension identified was the pro-
vision of information about how the ICC was calculated.
Within this, people felt it would be important to know:
• what method had been used to calculate the ICC (for
example, whether by ANOVA or by some other method);
• the software program used to calculate the ICC, as differ-
ent packages can give different results (not all packages
use the same definition of average cluster size [13]);
• what data were used to calculate the ICC – for example
whether the ICC was calculated from control data only,
from both control and intervention data, using pre-inter-
vention data only or post intervention; and
• whether any adjustment had been made for covariates
when the ICC had been calculated. Adjusting for covari-
ates leads, in general, to smaller ICCs, as some of the
between cluster variation may be explained by cluster
level factors [18].
Precision of the ICC
The final dimension suggested was some information on
the precision of the ICC estimate. Confidence intervals
were suggested as the primary mechanism for providing
information on the precision of the ICC, but the number
of clusters together with the average cluster size and the
range of cluster sizes (or some other measure of spread)
were also put forward as appropriate descriptors.
Discussion
Cluster randomized trials are increasingly being used in
the health care field, and there is a need to ensure that the
information presented in their reports is useful and aids
interpretation of the trial. Within cluster trials, ICCs for
trial outcomes are widely recognised as key items of infor-
mation that should be reported [3,13]. To date, however,
there has been little information to guide researchers on
how to describe the ICC, resulting in different researchers
providing different information in trial reports. In many
trials, if ICCs have been reported at all, authors simply
provide point estimates of the observed ICCs and no other
information. In contrast a few authors have provided
comprehensive information, allowing readers to interpret
the data easily. For example, Gulliford and colleagues
reported extensive information to aid the interpretation of
ICC estimates presented including the setting, the type of
cluster, the average cluster size, the number of clusters, the
prevalence of the outcome, the method of calculation, the
separate variance components and the design effect [15].
Similarly, Smeeth and Ng [16] provided extensive infor-
mation on the dataset their ICCs were calculated from and
also included information on prevalence of the outcomes,
the standard error of each ICC, the average cluster size for
each outcome, and the separate within- and between-
components of variation.
The results of the survey outlined in this paper have
shown that there is consensus amongst researchers in the
field as to which factors are important when describing an
ICC. We have presented a potential framework for the
reporting of ICCs, linking three main dimensions –
descriptions of the dataset, the method of ICC calculation
and the precision of the ICC estimate. The framework is
also likely to be straightforward to adopt in practice as the
data requirements outlined within the framework are gen-
erally readily available. The inclusion of extensive data
about the dataset may require additional journal report-
ing space but with the advent of web-based supplementa-
tion of journal articles this should not pose additional
burden on authors or journal editors.
The study reported here is not without limitations, how-
ever. Whilst every effort was made to identify a compre-
hensive sampling frame, we accept that our survey
population was relatively opportunistic, although there
was widespread representation from different countries,
and known leaders in the field were surveyed.
Open-text format was used in the questionnaire to allow
respondents to think expansively and not be constrained
by a potentially non-representative framework. By using
an open-text format, however, we cannot be sure that each
respondent detailed an exhaustive list of suggestions. We
also cannot attribute any ranking to the relative impor-
tance of each suggestion both within respondent and
across respondents. If time and resources could have
allowed, it would have been beneficial if all the sugges-
tions received could have been listed on a second ques-
tionnaire and dispatched to all participants for consensus
and ranking. In addition, a single researcher coded the
suggestions received. This could have inadvertently
resulted in some bias being introduced into the interpre-
tation of free-text responses. By having a single coder,
however, we can be reassured that suggestions were coded
in a consistent fashion.
The focus of the survey was on the reporting of the tradi-
tional ICC rather than the related statistic, k, which is
sometimes used in sample size calculations and analyses
of cluster randomized trials. This k-statistic has been sug-
gested for outcomes that are expressed in terms of patient-
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years [19]. The traditional ICC was the focus of this survey
as it is the more commonly used statistic in the reporting
of cluster randomized trials. A further survey of statisti-
cians for whom the k-statistic is particularly relevant
could, however, yield different results.
The introduction of the CONSORT statement has been
instrumental in improving the standards of reporting in
clinical trials [20,21]. It has been widely adopted by med-
ical journals worldwide including both general and dis-
ease-specific journals. It is important, therefore, that the
factors identified from this survey are considered in any
statement relating to cluster randomized trials.
Conclusions
In conclusion, this paper has demonstrated the develop-
ment of a comprehensive framework for the reporting of
ICCs. If adopted into routine practice, it has the potential
to facilitate the interpretation of the cluster trial being
reported and should help the development of new trials in
the area. Further research into the descriptors most appro-
priate to the reporting of the related k-statistic would be
beneficial.
Competing interests
None declared.
Authors' contributions
MKC and JMG conceived the idea for the study. MKC car-
ried out the survey, coded responses and analysed the
data. MKC wrote the first draft of the paper. MKC, JMG
and DRE were all involved in the development and refine-
ment of subsequent drafts. MKC is the guarantor for the
study.
Additional material
Acknowledgements
The Health Services Research Unit is funded by the Chief Scientist Office 
of the Scottish Executive Health Department. The views expressed are not 
necessarily those of the funding body.
References
1. Pocock SJ: Clinical trials: a practical approach Chichester: Wiley; 1983. 
2. Campbell MK, Grimshaw JM: Cluster randomised trials: time for
improvement. BMJ 1998, 317:1171-2.
3. Donner A, Klar N: Design and analysis of cluster randomization trials in
health research New York: Arnold; 2000. 
4. Murray DM: The design and analysis of group randomized trials Oxford:
Oxford University Press; 1998. 
5. Donner A, Koval JJ: Design considerations in the estimation of
the intraclass correlation. Ann Hum Genet 1982, 46:271-277.
6. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Rennie D,
Schulz KF, Simel DL, Stroup DF: Improving the quality of report-
ing of randomized controlled trials. The CONSORT
Statement. JAMA 1996, 276:637-9.
7. Moher D, Schultz K, Altman DG, for the CONSORT Group: The
CONSORT statement: revised recommendation for
improving the quality of reports of parallel-group ran-
domised trials. Lancet 2001, 357:1191-94.
8. MacLennan GS, Ramsay CR, Mollison J, Campbell MK, Grimshaw JM,
Thomas RE: Room for improvement in the reporting of clus-
ter randomised trials in behaviour change research
[abstract]. Control Clin Trials 2003, 24:69S-70S.
9. Eldridge SM, Ashby D, Feder G, Rudnicka AR, Ukoumunne OC: Les-
sons for cluster randomized trials in the twenty-first century:
a systematic review of trials in primary care. Clinical Trials 2004,
1:80-90.
10. Isaakidis P, Ioannidis JPA: Evaluation of cluster randomized con-
trolled trials in sub-Saharan Africa. Am J Epidemiol 2003,
158:921-6.
11. Elbourne D, Campbell MK: Extending the CONSORT state-
ment to cluster randomised trials: for discussion. Stat Med
2001, 20:489-496.
12. Campbell MK, Elbourne DR, Altman DG, for the CONSORT group:
The CONSORT statement: extension to cluster randomised
trials. BMJ 2004, 328:702-8.
13. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JA, Burney PG:
Methods for evaluating area-wide and organization-based
interventions in health and health care: a systematic review.
Health Technol Assess 1999, 3(5):iii-92.
14. Campbell MK, Grimshaw JM, Steen N, for the Changing Professional
Pratice in Europe Group: Sample size calculations for cluster
randomised trials. J Health Serv Res Policy 2000, 5:12-16.
15. Gulliford M, Ukoumunne O, Chinn S: Components of variance
and intraclass correlations for the design of community
based surveys and intervention studies: data from the health
survey for England 1994. Am J Epidemiol 1999, 149:876-883.
16. Smeeth L, Ng E: Intraclass correlation coefficients for cluster
randomized trials in primary care: data from the MRC trial
of the assessment and management of older people in the
community. Control Clin Trials 2002, 23:409-421.
17. Directory of Academic Statisticians  [http://www.swan.ac.uk/
statistics/das/]
18. Feng Z, Diehr P, Yasui Y, Evans B, Beresford S, Koepsell TD: Explain-
ing community-level variance in group randomized trials.
Stat Med 1999, 18:539-556.
19. Hayes RJ, Bennett S: Simple sample size calculation for cluster-
randomized trials. Int J Epidemiol 1999, 28:319-26.
20. Moher D, Jones A, Lepage L, for the CONSORT Group: Use of
CONSORT Statement and quality of reports of randomized
trials: a comparative before-and-after evaluation. JAMA 2001,
285:1992-5.
21. Egger M, Juni P, Bartlett C, for the CONSORT Group: Value of flow
diagrams in reports of randomized controlled trials. JAMA
2001, 285:1996-9.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2288/4/9/prepub
Additional File 1
Questionnaire sent to participants
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2288-4-9-S1.doc]
